Stock listing

BMV:SPRO Spero Therapeutics, Inc. Acciones

Mexican listing (BMV) of Spero Therapeutics, Inc. · home listing NASDAQ:SPRO

Follow Spero Therapeutics, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:SPRO

$1.10 USD -0.03 (-2.7%)

Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:SPRO

Since Jul 6, 2026 -49.8% · daily closes, Jul 6, 2026 – Oct 16, 2026, adjusted for splits
Day range
$1.09 – $1.17 USDOct 16, 2026
Volume
361,227 sharesOct 16, 2026
Market value
$64.06M USDAt the close on Oct 16, 2026 · price × 58.23M shares outstanding
Spero Therapeutics, Inc. logo
Ticker
BMV:SPRO
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
BMV
Currency
MXN

What changed lately

Calls

Replays

  • Spero Therapeutics (NASDAQ:SPRO) Q2 2026 Earnings Call

    Wed, Aug 12, 2026 · 5:00 PM ET

    Watch Transcript

  • Spero Therapeutics (NASDAQ:SPRO) Q2 2025 Earnings Call

    Tue, Aug 12, 2025 · 4:30 PM ET

    Watch Transcript

  • Spero Therapeutics (NASDAQ:SPRO) Q4 2024 Earnings Call

    Thu, Mar 27, 2025 · 4:30 PM ET

    Watch Transcript

Latest news

Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference

Oct 15, 2026

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 2, 2026

Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

Sep 2, 2026

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

Aug 12, 2026

Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

Aug 4, 2026

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

Jul 27, 2026

Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

Jul 14, 2026

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

Jul 14, 2026

Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

Jul 14, 2026

Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)

Jun 17, 2026

All Spero Therapeutics, Inc. news

Decks

Spero Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
18 in the last 12 months · 110 in all · newest Oct 15, 2026 · oldest 2019
Calls
16 calls with a replay · 16 with a transcript · latest Aug 12, 2026
Decks
19 decks · latest Aug 12, 2026

Where Spero Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:SPRO · Home listingNASDAQUnited StatesUSD
LS Exchange:A2H63FLS ExchangeGermanyEUR
Lang & Schwarz:A2H63FLang & SchwarzGermanyEUR
BOATS:SPROBOATSUnited StatesUSD
gettex:2HAgettexGermanyEUR
Tradegate:2HATradegateGermanyEUR
Dusseldorf:2HADusseldorfGermanyEUR
Frankfurt:2HAFrankfurtGermanyEUR
Munich:2HAMunichGermanyEUR
Stuttgart:2HAStuttgartGermanyEUR
BIVA:SPROBIVAMexicoMXN
BMV:SPRO · This pageBMVMexicoMXN

Log in to ask 6ix AI your own questions about Spero Therapeutics, Inc.